Risk factors of drug-resistant epilepsy in children under three-year-old
Abstract
Background Repeated seizures may result in chronic injury to the brain, triggering the neuroplasticity process that can cause or augment existing pathological processes. High neuroplasticity during first 3 year of life may influence the clinical course and outcome of children with epilepsy.
Objective To evaluate initial risk factors and evolution risk factors during treatment to predict drug-resistant epilepsy in children under 3 years old. Initial risk factors consist of initial seizure frequency, seizure type, imaging result, history of febrile convulsion, neurodevelopmental status and initial electroencephalography (EEG) result. Evolution risk factors evaluate changes in initial risk factors and seizure control after treatment. Evolution risk factors consist of early response to therapy (seizure control during the first 6 months of treatment), evolution of seizure type and frequency, changes in EEG (background rhythm and epileptiform discharges) during treatment and neurodevelopmental evolution.
Methods This retrospective cohort study used medical record data of pediatric patients 1 month to 3 years old with drug-resistant epilepsy seeking treatment at Cipto Mangunkusumo Hospital, Anakku Clinic Pondok Pinang, and National Brain Center Hospital, Jakarta, from 2015 to 2020.
Results Thirty-three subjects met drug-resistant epilepsy criteria. Abnormal EEG was the only initial risk factor significantly associated with drug-resistant epilepsy (OR 4.48; 95%CI 1.82 to 11.03; P=0.001). Increased seizure frequency (aOR 7.0; 95%CI 1.0 to 49.7; P=0.048) and seizure persistence during the first six months of treatment (aOR 10.92; 95%CI 2.6 to 45.87; P=0.01) were significantly related with drug-resistant epilepsy.
Conclusion Abnormal initial EEG result was the only initial risk factor associated with drug-resistant epilepsy. Evolution risk factors associated with drug-resistant epilepsy were increased seizure frequency and seizure persistence in the first six months of treatment.
References
2. Knickmeyer R, Gouttard S, Kang C, Evans D, Wilber K, Smith JK, et al. A structural MRI study of human brain development from birth to 2 years. J Neurosci. 2008;28:12176-82. DOI: https://doi.org/10.1523/JNEUROSCI.3479-08.2008
3. Holmes G. Effect of seizure on the developing brain and cognition. Semin Pediatr Neurol. 2016;23:120-6. DOI: https://doi.org/10.1016/j.spen.2016.05.001
4. Jarero-Basulto JJ, Gasca-Martinez Y, Rivera-Cervantes MC, Ureña-Guerrero ME, Feria-Velasco AI, Beas-Zarate C. Interactions between epilepsy and plasticity. Pharmaceuticals. 2018;11:1-18. DOI: https://doi.org/10.3390/ph11010017
5. Kwan P, Arzimanoglou A, Berg A, Brodie MJ, Hauser W, Mathern G, et al. Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Theurapetic Strategies. Epilepsia. 2010;51:1069-77. DOI: https://doi.org/10.1111/j.1528-1167.2009.02397.x
6. Wang X, Wang H, Zhu L, Da X, Liu L. Risk factors for drug-resistant epilepsy: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e16402. DOI: https://doi.org/10.1097/MD.0000000000016402
7. Mangunatmadja I. Prediction of clinical outcome in patients with focal epilepsy under 3 years of age: the role of clinical evolution and electroencephalography and magnetic resonance imaging. [dissertation]. Jakarta: Universitas Indonesia; 2012.
8. Wirrel E, Kisiel L, Mandrekar J, Nickels K. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: a retrospective, population-based study. Epilepsia. 2012;53:1563-9. DOI: https://doi.org/10.11111/j.1528-1167.2012.03562.x
9. Yildiz E, Gunes D, Bektas G, Uzunhan T, Tatli B, Calliskan M, et al. Predictive factors of drug-resistant epilepsy in children presenting under 2 years of age: experience of a tertiary center in Turkey. Acta Neurol Belg. 2018;118:71-5. DOI: https://doi.org/10.1007/s13760-017-0850-3
10. Widodo D. Faktor risiko terjadinya epilepsi yang sukar disembuhkan pada anak berumur di bawah 5 tahun. [dissertation]. Jakarta: Universitas Indonesia; 2012.
11. Handryastuti S, Mangunatmadja I. Risk factors influencing the outcomes in infants with epilepsy. Paediatr Indones. 2007;47:202-6. DOI: https://doi.org/10.14238/pi47.5.2007.202-6
12. Mangunatmadja I, Mulyani D, Pardede S, Tridjaja B, Wulandari H. Risk factors for intractable epilepsy in children with generalized epilepsy. J Indon Med Assoc. 2019;69:59 -65. DOI: https://doi.org/10.47830/jinma-vol.69.2-2019-72
13. Xia L, Ou S, Pan S. Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy as a predictor of long-term outcome. Front Neurol. 2017;8:658. DOI: https://doi.org/10.3389/fneur.2017.00658
14. Sinaga N. Respons awal obat antiepilepsi monoterapi pada pasien epilepsi baru. [thesis]. Jakarta: Universitas Indonesia; 2017.
15. Sillanpaa M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood onset epilepsy. Brain. 2009;132:989-98. DOI: https://doi.org/10.1093/brain/awn357
16. Auvin S. Pathophysiology of seizures in the developing brain. In: Pellock JM, Nordli DR, Sankar R, Wheless JW, editors. Pellock’s pediatric epilepsy: diagnosis and therapy. New York: Demos Medical Publishing; 2017. p. 3-19.
17. Avanzini G, Depaulis A, Tassinari A, de Curtis M. Do seizures and epilepstic activity worsen epilepsy and deteriorate cognitive function? Epilepsia. 2013;54:14-21. DOI: https://doi.org/10.11111/epi.12418
18. Yehezkel B. Epilepsies and neuronal plasticity: for better or for worse? Dialogues Clin Neurosci. 2008;10:17-27. DOI: https://doi.org/10.31887/DCNS.2008.10.1/ybenari
Copyright (c) 2025 Suryawati Sukmono, Irawan Mangunatmadja, Sudung O. Pardede
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2025-02-28
Published 2025-02-28
